Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $60.60.

Several research analysts recently commented on ESTA shares. BTIG Research raised their price objective on shares of Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, October 14th. JPMorgan Chase & Co. cut their price target on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Citigroup boosted their price objective on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. Finally, Stephens restated an “overweight” rating and issued a $68.00 target price on shares of Establishment Labs in a research note on Wednesday, August 7th.

Establishment Labs Price Performance

NASDAQ ESTA opened at $42.38 on Friday. The company has a market cap of $1.18 billion, a PE ratio of -16.43 and a beta of 1.20. The company has a quick ratio of 2.91, a current ratio of 4.44 and a debt-to-equity ratio of 4.30. The firm’s 50-day simple moving average is $43.37 and its two-hundred day simple moving average is $45.79. Establishment Labs has a 52 week low of $21.25 and a 52 week high of $60.12.

Institutional Investors Weigh In On Establishment Labs

Several large investors have recently added to or reduced their stakes in ESTA. BNP Paribas Financial Markets raised its holdings in shares of Establishment Labs by 32,968.7% in the 1st quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock valued at $4,949,000 after acquiring an additional 96,928 shares in the last quarter. Swiss National Bank raised its stake in Establishment Labs by 13.6% in the first quarter. Swiss National Bank now owns 37,500 shares of the company’s stock valued at $1,909,000 after purchasing an additional 4,500 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new stake in Establishment Labs in the first quarter valued at approximately $263,000. William Blair Investment Management LLC bought a new stake in Establishment Labs during the first quarter valued at approximately $21,415,000. Finally, Vanguard Group Inc. increased its holdings in shares of Establishment Labs by 11.8% in the 1st quarter. Vanguard Group Inc. now owns 77,798 shares of the company’s stock worth $3,960,000 after buying an additional 8,210 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.